Any updates or news on Gt20029? Chat 11/3/2024
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
View this post in the Community →
Similar Community Posts Join
6 / 320 resultscommunity Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Current and possible future Alternatives for fin?
A user is seeking alternatives to finasteride for hair loss during a planned break for family planning reasons. They inquire about pyrilutamide, cosmern, and other potential future treatments.
community Where are we with GT20029 ? Realistic Timeline ?
GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.
community Kintor is conducting a phase III trial of Pyrilutamide in combination with Minoxidil 💀
Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.
Related Research
6 / 11 resultsresearch Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.